Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New Zealand for its HB0056, a bispecific antibody (BsAb) targeting thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11), clearing the way for the drug to enter Phase I clinical studies for asthma treatment.
HB0056 is the world’s first bispecific antibody of its kind to enter clinical trials, capable of simultaneously blocking both IL-11 and TSLP signaling pathways, thereby inhibiting their biological activities. The in vitro biological activity of HB0056 in blocking the TSLP signaling pathway is significantly superior to tezepelumab, a marketed TSLP-targeted monoclonal antibody developed by AstraZeneca. The drug also shows potential for dual-target synergistic effects by inhibiting the expression of fibrosis-related genes in MRC-5 cells (human embryonic lung fibroblasts).
In vivo pharmacological studies have demonstrated HB0056’s superior improvement effects on serum OVA-specific IgE, eosinophil count in BALF lavage fluid, and eosinophil infiltration indicators in lung tissue, highlighting its potential as a dual-target synergistic therapy for asthma.- Flcube.com
